BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

CSIRO Invests A $2 Million in Avexa Limited (AVX.AX)'s HCV Program


7/15/2009 6:54:09 AM

Bookmark and Share

MELBOURNE, Australia--(BUSINESS WIRE)--Avexa Limited (ASX:AVX - News) today announced that the Commonwealth Scientific and Industrial Research Organisation (CSIRO) will invest up to A$2M into Avexa’s hepatitis C virus (HCV) program through the CSIRO’s Australian Growth Partnerships (AGP) program.

“HCV is a serious condition particularly for those patients who are chronically infected. As one of the largest and most diverse scientific research organisations in the world, we are excited to work with the CSIRO to better understand this terrible disease,” said Dr Julian Chick, Chief Executive Officer of Avexa.

The agreement will enable Avexa and the CSIRO to combine skill sets and abilities to discover new medicines for Hepatitis C. Hepatitis C is an infectious disease affecting over 180 million people globally and is a leading cause of chronic liver disease resulting in liver inflammation, cirrhosis and liver cancer. The disease is blood-borne and the virus spreads within its host by replicating its RNA and using this to make the components that form new viruses. The Avexa/CSIRO collaboration will initially focus on the identification of small molecule inhibitors targeting the NS5B RNA polymerase which is essential to this replication process.

Under the terms of the agreement, CSIRO could either share in the upside of the program if it is successful, or convert its $2M investment into equity once the program is complete, which is expected to be in two years. In some circumstances Avexa may elect, or be required, to repay the investment.

About the Commonwealth Scientific and Industrial Research Organisation and AGP

The Commonwealth Scientific and Industrial Research Organisation (CSIRO) is Australia’s premier research organisation which provides scientific solutions to industry, governments and communities around the world. The CSIRO’s role is to deliver great science and innovative solutions for industry, society and the environment. The organisation works on new ways to improve quality of life, as well as the economic and social performance of a number of industry sectors through research and development. Australian Growth Partnerships (AGP) is a competitive, merit-based pilot funding program managed by CSIRO. CSIRO has been allocated funds by the Commonwealth Government to provide funding to high potential, technology-receptive small and medium enterprises in order that they can access CSIRO research and development capability and intellectual property. For more information, visit www.csiro.au/AGP

About Hepatitis C Virus

Of the 180 million people globally that the World Health Organization estimates are infected with hepatitis C virus, or HCV, 100 million have a chronic infection. According to the Center for Disease Control approximately 3.2 million people in the United States are chronically infected. Studies on progression of disease in chronically infected people indicate that 70% of these chronically infected patients develop some form of chronic liver disease, including, in some cases, cirrhosis or liver cancer. The HCV market is forecast to grow to $4.4 billion in 2010 and $8.8 billion in 2015.

About Avexa

Avexa Limited is a Melbourne-based biotechnology company with a focus on research and development of small molecules for the treatment of infectious diseases. Avexa has dedicated resources and funding for key projects including apricitabine (ATC), its HIV integrase program, its HCV polymerase program and an antibiotic program for antibiotic-resistant bacterial infections. The Company’s lead program, ATC, is an anti-HIV drug that has successfully completed the 16 week dose determination step of its worldwide Phase III trial.

www.avexa.com.au

Contact:

Avexa Limited Dr Julian Chick, +61 3 9208 4300 Chief Executive Officer Stephen Kerr, + 61 3 9208 4300 CFO & Company Secretary or Blueprint Life Science Group AU: Investor Relations Sabrina Antoniou, + 61 2 9519 5537 US: Investor Relations Remy Bernarda, + 1 415-375-3340 ext. 2022

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES